Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders (2023) Vol. 327, pp. 120-127
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Must Psilocybin Always “Assist Psychotherapy”?
Guy M. Goodwin, Ekaterina Malievskaia, Gregory A. Fonzo, et al.
American Journal of Psychiatry (2023) Vol. 181, Iss. 1, pp. 20-25
Closed Access | Times Cited: 95
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
Guy M. Goodwin, Megan Croal, David Feifel, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 10, pp. 1492-1499
Open Access | Times Cited: 81
History repeating: guidelines to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 51
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 23
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 17
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
John H. Krystal, Alfred P. Kaye, Sarah Jefferson, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 49
Open Access | Times Cited: 30
History repeating: A roadmap to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
(2023)
Open Access | Times Cited: 23
Psilocybin: From Psychiatric Pariah to Perceived Panacea
Gregory A. Fonzo, Aaron Wolfgang, Bryan Barksdale, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 54-78
Closed Access | Times Cited: 1
Beyond the 5-HT2AReceptor: Classic and Nonclassic Targets in Psychedelic Drug Action
Lindsay P. Cameron, Joseph Benetatos, Vern Lewis, et al.
Journal of Neuroscience (2023) Vol. 43, Iss. 45, pp. 7472-7482
Open Access | Times Cited: 21
Cardiovascular safety of psychedelic medicine: current status and future directions
Agnieszka Wsół
Pharmacological Reports (2023) Vol. 75, Iss. 6, pp. 1362-1380
Open Access | Times Cited: 20
Spiritual health practitioners’ contributions to psychedelic assisted therapy: A qualitative analysis
Caroline Peacock, Jennifer S. Mascaro, Erin Brauer, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0296071-e0296071
Open Access | Times Cited: 6
Do the therapeutic effects of psilocybin involve actions in the gut?
Felicia Reed, Claire J. Foldi
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 2, pp. 107-117
Closed Access | Times Cited: 6
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Daniel Meling, Rebecca Ehrenkranz, Sandeep M. Nayak, et al.
Psychoactives (2024) Vol. 3, Iss. 2, pp. 215-234
Open Access | Times Cited: 6
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 6
Psilocybin’s effects on cognition and creativity: A scoping review
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 635-648
Open Access | Times Cited: 15
Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis
Kwonmok Ko, Ben Carter, Anthony J. Cleare, et al.
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 2105-2113
Open Access | Times Cited: 13
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics
Antonella Campanale, Antonio Inserra, Stefano Comai
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111058-111058
Open Access | Times Cited: 5
Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression
Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 5
UK medical students’ self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study
Charlie Song-Smith, Edward Jacobs, James Rucker, et al.
BMJ Open (2024) Vol. 14, Iss. 3, pp. e083595-e083595
Open Access | Times Cited: 4
Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties
Mazen A. Atiq, Matthew Baker, Jennifer L. Vande Voort, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 4
Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps
Eyal Kurzbaum, Tomáš Páleníček, Amiel Shrchaton, et al.
Journal of Fungi (2025) Vol. 11, Iss. 2, pp. 99-99
Open Access
Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects
Carrie Cuttler, Amanda Stueber, Jonathan J. Simone, et al.
Journal of Psychoactive Drugs (2025), pp. 1-13
Closed Access
Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches
Aline Silva de Miranda, Eliana Cristina de Brito Toscano, Venugopal Reddy Venna, et al.
Expert Opinion on Drug Discovery (2025), pp. 1-15
Closed Access
The Trouble With Psychedelic Cacti: Conflicting Meanings of San Pedro and Peyote
Liam Engel, Mitchell Low
Contemporary Drug Problems (2025)
Closed Access
Microglial Phagocytosis and Regulatory Mechanisms: Key Players in the Pathophysiology of Depression
Man Wang, G. L. Jin, Tingting Duan, et al.
Neuropharmacology (2025) Vol. 271, pp. 110383-110383
Closed Access
Page 1 - Next Page

Scroll to top